ARPA-H launched ADVOCATE, a program that funds agentic health technology development, including early-detection and diagnostic-focused projects. The agency’s Rare Disease AI/ML for Precision Integrated Diagnostics effort backs multiple initiatives intended to accelerate when clinicians can identify disease. The initiative also reinforces ARPA-H’s broader strategy of converting platform-level AI capabilities into FDA-relevant tooling. Industry will likely track how quickly projects move from prototypes into validation pathways suitable for clinical and regulatory review.